GRAIL, Inc. (GRAL)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
$143.66+3.03%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-11-04
Research Workspace
Put GRAL beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Life Sciences Tools & Services: structurally weak cohort (structural / late-cycle), so the cyclical early-warning is suppressed.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRanks in the weakest quality tier of its industry — roughly the bottom 40%, softest on free-cash-flow margins.
View QualityManagement screens weak on capital allocation, margins, market reaction to earnings.
View ManagementExpectations look high — the market is pricing in about 54% growth a year, above the roughly 32% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 3% on a typical day and fell roughly 63% in its worst 12-month stretch.
View RiskGrail's cancer detection test has to keep compounding to justify the price. Revenue growth slowed to 4% in the third quarter of 2026. The company beat earnings estimates by 20.5% in that period. It trades at 38x sales versus a 5x peer median. The market is pricing in more growth than we forecast. Revenue growth must hit the 22-32% target to support this premium. Peer multiples imply a price about 54% below where it trades. This read is provisional. Our read remains intact.
Trailing returns as of 2026-11-04. GRAL is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 10 analysts currently covering GRAL (as of Nov 2026).
Based on 6 Wall Street analysts offering 12-month price targets for GRAL in the last 4 months.
Continue this research
Compare GRAL with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| GRAL Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Compare the value case
Put GRAL next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Complete FDA PMA submission and obtain advisory committee review
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $143.66
The last 12 months of price, then the range of analyst 12-month targets from today’s $143.66.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
FDA timeline clarity reduces regulatory uncertainty.
Threatens: Achieve revenue growth of 22-32% in 2026
Revenue miss directly undermines 2026 growth target.
Advances: Complete FDA PMA submission and obtain advisory committee review
FDA panel support is a major regulatory milestone.
Advances: Complete FDA PMA submission and obtain advisory committee review
FDA panel vote supports regulatory progress for Galleri test.
Advances: Complete FDA PMA submission and obtain advisory committee review
FDA panel backing supports regulatory objective for Galleri test.
Advances: Complete FDA PMA submission and obtain advisory committee review
Positive FDA comments support regulatory objective.
Advances: Complete FDA PMA submission and obtain advisory committee review
FDA panel vote supports regulatory progress for Galleri.
Reimbursement concerns could hinder commercial growth.
